INFOGRAPHIC: Patent Losses Characterize Japan's Challenging Pharma Future
Executive Summary
Although 10 of Japan’s largest pharma companies look set to add $11bn in revenues over the next nine years, a CAGR of only 1% reflects an expected $4.8bn in patent expiries, leaving Japanese pharma heads relying on innovation for the next phase of the region’s major wins.